Maxcyte (MXCT) Change in Receivables (2020 - 2026)

Maxcyte (MXCT) has reported Change in Receivables for 7 consecutive years, with -$324000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables fell 236.13% year-over-year to -$324000.0 in Q2 2026; TTM through Jun 2026 was -$1.8 million, a 253.31% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 million, up 6.36% from the prior year.
• Change in Receivables was -$324000.0 for Q2 2026 at Maxcyte, down from $743000.0 in the prior quarter.
• Over five years, Change in Receivables peaked at $4.0 million in Q4 2022 and troughed at -$4.8 million in Q4 2025.
• A 5-year average of -$145111.1 and a median of $61450.0 in 2022 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables soared 46455.56% in 2023 and plunged 4031.97% in 2025, its largest moves.
• Over 5 years, Change in Receivables stood at $4.0 million in 2022, then sank by 141.25% to -$1.7 million in 2023, then jumped by 107.37% to $122000.0 in 2024, then sank by 4031.97% to -$4.8 million in 2025, then jumped by 93.25% to -$324000.0 in 2026.
• The last three Change in Receivables figures came in at -$324000.0 (Q2 2026), $743000.0 (Q1 2026), and -$4.8 million (Q4 2025), per Business Quant data.